Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$11.98 +0.24 (+2.04%)
As of: Sep 30, 2026 · 12:50 PM EDT

Monte Rosa Therapeutics, Inc. (GLUE) EBIT Margin (2024 - 2026)

Updated

Monte Rosa Therapeutics' EBIT Margin was -547.84% in Q2 2026, down 480.78 percentage points from -67.06% a year earlier but up 640.62 percentage points from the prior quarter.

Analysis

Monte Rosa Therapeutics, Inc. (GLUE) EBIT Margin (2024 - 2026) Analysis & Trends

On a trailing twelve-month basis, Monte Rosa Therapeutics' EBIT Margin was -633.04% through Jun 30, 2026, down 641.45 percentage points year-over-year; for FY2025, it was -43.83%, up 63.43 percentage points from FY2024.

  • In earlier years, EBIT Margin was -107.26% in FY2024.
  • Quarterly EBIT Margin has moved between -3284.49% (Q1 2024) and 51.85% (Q1 2025) over five years.
  • Compared with a year earlier, EBIT Margin has declined for three straight quarters, with an average year-over-year change of +77.32 percentage points over the last six quarters.
  • Per Business Quant data, GLUE's EBIT Margin in the three quarters before Q2 2026 was -1188.46% (Q1 2026), -1787.67% (Q4 2025) and -258.26% (Q3 2025).
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -547.84%
Mar 31, 2026 -1,188.46%
Dec 31, 2025 -1,787.67%
Sep 30, 2025 -258.26%
Jun 30, 2025 -67.06%
Mar 31, 2025 51.85%
Dec 31, 2024 21.44%
Sep 30, 2024 -287.84%
Jun 30, 2024 -695.25%
Mar 31, 2024 -3,284.49%
API Access

Monte Rosa Therapeutics, Inc. EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=GLUE&period=max&api_key=YOUR_API_KEY